Nidanilimab (CAN04) is a fully humanized IL1RAP monoclonal antibody with a Kd value of 1.10 pM. It exhibits antitumor activity by disrupting the IL1alpha and IL1beta signaling pathways and inducing the immune system to destroy tumor cells. Nidanilimab can be used to study solid cancers, such as non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC).
Purity:
>95%
CAS Number:
[2171061-85-9]
Target:
IL Receptor|||Interleukin
* VAT and and shipping costs not included. Errors and price changes excepted
